FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/08/2026
Voltar para busca
Dado oficial do USPTO
ESQLABS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
23
Atualização mais recente
12/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 41, 42
Data de depósito
27/11/2024
Data de registro
12/05/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/05/2026
Última transação
12/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
ONUOHA, UKACHUKWU FREDERICK
Unidade examinadora
O20
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
esqlabs GmbH
Representantes
Kristen H. Mowery Hodgson Russ LLP
Classificação técnica
Classes Nice
Classe 9Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Blank digital storage media; Electronic publicationsnamely training manuals in electronic form; downloadable computer software and software platforms for modelling and simulationin particular in the field of pharmacychemistry or plant protection; downloadable modelling and simulation computer software and platforms for physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP); downloadable computer software and software platforms for investigating organ damage; downloadable computer software and software platforms for investigating drug-drug interactions (DDI); downloadable computer software and software platforms for translational modelling for human initial dose prediction; downloadable computer software and software platforms for developingcalculating and analysing mathematical models and simulationsin particular in the field of life sciences; downloadable graphical user interface software being software and software platforms with graphical user interfaces for various operating systems and platforms; downloadable computer software and software platforms for solving numerical problems; downloadable computer software and software platforms for analysing datain particular statistically; downloadable computer software and software platforms for graphical visualisation of simulation results and observed data; downloadable computer software packages for programming languages in the nature of downloadable software development kits (SDK); electronic databases in the field of pharmacychemistry or plant protection recorded on computer media
Classe 41
Educationtraining and teachingteachingtrainingtutoring and courses of instruction at the undergraduategraduate and post-graduate level; training and education services being instruction in the field of pharmacychemistry or plant protection; organisation and provision of training courses in the field of pharmacychemistry and plant protection; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for modelling and simulationin particular in the fields of pharmacychemistry and plant protection; organisation and provision of training coursesconferencesworkshops and seminars relating to physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platforms; organisation and provision of training coursesconferencesworkshops and seminars relating to the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for investigating organ damage; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for investigating drug-drug interactions (DDI); organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for translational modelling for initial dose prediction in humans; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for the developmentcalculation and analysis of mathematical models and simulationsin particular in the field of life sciences; organisation and provision of training coursesconferencesworkshops and seminars relating to graphical user interface software and software platforms for various operating systems and platforms; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for solving numerical problems; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for the statistical evaluation of data; organisation and provision of training coursesconferencesworkshops and seminars relating to software and software platforms for the graphical representation of simulation results and observed data; organisation and provision of training coursesconferencesworkshops and seminars relating to the development and implementation of packages for programming languages being software development kits (SDK); organisation and provision of training coursesconferencesworkshops and seminars relating to the creation and integration of electronic databases; creation of training materials in the field of pharmacychemistryplant protection both in hard copy and electronic forms including booksvideossoftware; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for modelling and simulationin particular in the fields of pharmacychemistry and plant protection; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platforms; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for studying organ damage; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for the study of drug-drug interactions (DDI); creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for translational modelling for human initial dose prediction; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for developingcalculating and analysing mathematical models and simulationsin particular in the field of life sciences; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to graphical user interface software and software platforms for different operating systems and platforms; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for solving numerical problems; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for statistical analysis of data; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to software and software platforms for the graphical visualisation of simulation results and observed data; creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to the development and implementation of packages for programming languagesbeing software development kits (SDK); creation of training materialsboth in hard copy and electronic forms including booksvideossoftwarerelating to the creation and integration of electronic databases
Classe 42
IT consulting services relating to installationmaintenance and repair of computer software; software as a service (SaaS) featuring software for modelling and simulation in the field of pharmacychemistry and plant protection; platform as a service (PaaS) featuring computer software platforms for modelling and simulation in the field of pharmacychemistry or plant protection; computer services for data analysescomputerized analysis and interpretation of data concerning pharmacychemistryplant protection; conducting of technical data analyses in the field of pharmacychemistry or plant protection; designdevelopmentprogramming and implementation of software and software platforms for modelling and simulationin particular in the field of pharmacychemistry or plant protection; designdevelopmentprogramming and implementation of physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platforms; designdevelopmentprogramming and implementation of software and software platforms for the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; designdevelopmentprogramming and implementation of software and software platforms for investigating organ damage; designdevelopmentprogramming and implementation of software and software platforms for investigating drug-drug interactions (DDI); designdevelopmentprogramming and implementation of software and software platforms for translational modelling for human initial dose prediction; designdevelopmentprogramming and implementation of software and software platforms for the developmentcalculation and analysis of mathematical models and simulationsin particular in the field of life sciences; designdevelopmentprogramming and implementation of software and software platforms with graphical user interfaces for various operating systems and platforms; designdevelopmentprogramming and implementation of software and software platforms for solving numerical problems; designdevelopmentprogramming and implementation of software and software platforms for statistical analysis of data; designdevelopmentprogramming and implementation of software and software platforms for the graphical visualisation of simulation results and observed data; designdevelopmentprogramming and implementation of packages for programming languages being software development kits (SDK); designdevelopmentprogramming and implementation of electronic databases recorded on computer media; provision of temporary use of online non-downloadable software and software platforms for modelling and simulationin particular in the field of pharmacychemistry or plant protection; provision of temporary use of online non-downloadable physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platformsin particular in the field of pharmacychemistry or plant protection; provision of temporary use of online non-downloadable software and software platforms for the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; provision of temporary use of online non-downloadable software and software platforms for the investigation of organ damage; provision of temporary use of online non-downloadable software and software platforms for investigating drug-drug interactions (DDI); provision of temporary use of online non-downloadable software and software platforms for translational modelling for human initial dose prediction; provision of temporary use of online non-downloadable software and software platforms for the developmentcalculation and analysis of mathematical models and simulationsin particular in the field of life sciences; provision of temporary use of online non-downloadable graphical user interface software being software and software platforms for various operating systems and platforms; provision of temporary use of online non-downloadable software and software platforms for solving numerical problems; provision of temporary use of online non-downloadable software and software platforms for analysing datain particular statistically; provision of temporary use of online non-downloadable software and software platforms for graphical visualisation of simulation results and observed data; technological and scientific consulting services in the field of pharmacychemistry or plant protection; IT consultancyadvisory and information services related to installationmaintenance and repair of computer software; IT consultancyadvisory and information services relating to software and software platforms for modelling and simulationin particular in the field of pharmacychemistry or plant protection; IT consultancyadvisory and information services relating to physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platformsin particular in the field of pharmacychemistry or plant protection; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for studying organ damage; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for investigating drug-drug interactions (DDI); IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for translational modelling for human initial dose prediction; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for the developmentcalculation and analysis of mathematical models and simulationsin particular in the field of life sciences; IT consultancyadvisory and information services relating to installationmaintenance and repair of graphical user interface computer software and software platforms for various operating systems and platforms; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for solving numerical problems; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for analysing datain particular statistically; IT consultancyadvisory and information services relating to installationmaintenance and repair of computer software and software platforms for the graphical visualisation of simulation results and observed data; IT consultancyadvisory and information services relating to the development and implementation of packages for programming languages being software development kits (SDK); IT consultancyadvisory and information services relating to the creation and integration of electronic databases; installationsetting up and maintenance of software; installationsetting up and maintenance of software and software platforms for modelling and simulationin particular in the field of pharmacychemistry or plant protection; installationsetting up and maintenance of physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP) modelling and simulation software and platforms; installationsetting up and maintenance of software and software platforms for the development of preclinical or clinical physiologically-based pharmacokinetics (PBPK) software models; installationsetting up and maintenance of software and software platforms for investigating organ damage; installingsetting up and maintenance of software and software platforms for investigating drug-drug interactions (DDI); installationsetting up and maintenance of software and software platforms for translational modelling for human initial dose prediction; installingsetting up and maintenance of software and software platforms for developingcalculating and analysing mathematical models and simulationsin particular in the field of life sciences; installingsetting up and maintenance of software and software platforms with graphical user interfaces for various operating systems and platforms; installingsetting up and maintenance of software and software platforms for solving numerical problems; installingsetting up and maintenance of software and software platforms for analysing datain particular statistically; installingsetting up and maintenance of software and software platforms for the graphical visualisation of simulation results and observed data; installationsetting up and maintenance of packages for programming languages being software development kits (SDK); installationsetting up and maintenance of electronic databases; medical and pharmaceutical research services
Publicações
Histórico de despachos e eventos da marca no USPTO.
23 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/05/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
12/05/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/03/2026
PUBO
PUBLISHED FOR OPPOSITION
24/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/03/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/02/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
26/02/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
26/02/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
26/02/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
26/02/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/01/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/01/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/01/2026
RFNT
REFUSAL PROCESSED BY IB
08/08/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/07/2025
RFRR
REFUSAL PROCESSED BY MPU
24/07/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/05/2025
CNRT
NON-FINAL ACTION WRITTEN
29/05/2025
DOCK
ASSIGNED TO EXAMINER
19/05/2025
MAFR
APPLICATION FILING RECEIPT MAILED
25/04/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/04/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/04/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ESQLABS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.